NP-12 // NP031112 // Zentylor // Tideglusib .
This study is ongoing, but not recruiting participants.
First Received: January 13, 2010 Last Updated: October 7, 2010
Brief title Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
Enrollment: 146
Study Start Date: December 2009
Estimated Study Completion Date: November 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Administrative Data
Organization name Noscira SA
Organization study ID NP031112-08B02
Sponsor Noscira SA
Collaborator i3 Research
Health Authority United States: Food and Drug Administration
Health Authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Health Authority Spain: Spanish Agency of Medicines
Health Authority Germany: Federal Institute for Drugs and Medical Devices
...
IMFORTE . Desde JazzPharma Siguen Anclados en los Resultados del Corte Intermedio Realizado Por ROCHE en 2024 Cuyos Datos Fueron Presentados en ASCO25 , Revista Especializada Y en la US-FDA ... Repetidos Ya Miles de Veces Sin Variar Ni una Sola Coma ... Queda Claro Qué Nada Nuevo Tienen ... Y Eso a Fecha de Hoy Da Qué Pensar ...
10 octubre 2010
ESMO . Erlotinib resultó más efectivo que otros utilizados en la terapia tradicional y mejoró las probabilidades de supervivencia de pacientes con ...
... cáncer de pulmón con mutaciones que activan el gen EGFR, divulgaron hoy científicos.
...
...
Suscribirse a:
Entradas (Atom)